

INDEX

A

- AAV serotype 2, intramuscular delivery of 89
- AAV serotype 6
 - concentration 96
 - GFP fluorescence and 103
 - histology of 91–92
 - intramuscular delivery
 - into adult mice 99–100
 - into neonate mice 100
 - isolation of 95
 - production of 89–90
 - purification via HPLC 95–96
 - titration using FACS analysis 96–97
- Amyotrophic lateral sclerosis (ALS)
 - demyelination of large axons 104–105
 - SOD1, mutations in 87–88
- Anesthetized mouse
 - intramuscular injection of AAV6 into 101
 - intratumoral injection of, set-up for 20
- Anopheles* mosquitoes
 - malaria and 63
 - RNAi-mediated silencing in
 - efficiency of 65, 66–67
 - injection of dsRNA 64, 66
 - stable 64–65

B

- B16-F10 GFP tumors
 - GFP gene expression in
 - fluorescence analysis 20–21
 - statistical analysis 21–22
 - injection of 19
 - RNA extraction for RNA knockdown validation
 - RNA yield 23–24
 - from stablized tissues 22–23
 - target gene mRNA levels 24
 - in vivo* electropulsation 19
- Blocking buffer 129–130

C

- Caenorhabditis elegans* 109, 128
- Carcinoembryonic antigen (CEA) 132
 - RNAi against 133–134
- C57Bl/6 mice 17
- cDNA synthesis 5x first-strand buffer for 130
- CEA, *see* Carcinoembryonic antigen (CEA)
- CEA mRNA, siRNA-mediated degradation of .. 132–136
 - RNAi against CEA 133–134
 - siRNA design 132–133
 - transient transfection of MCF7 cells 135
 - Western blot analysis 135–136
- Chitosan-based nanoparticle system 77

- cytotoxicity of 78, 82
- flow cytometry of 78, 81–82, 85
- formation of
 - interpolyelectrolyte complexes 79
 - materials for 78
- intraperitoneal injection of 84
- reverse transfection 78, 80–81
- storage and drying of
 - materials for 79
- TNF α secretion determination 79, 82–83
- transfection of
 - evaluation of 83
 - macrophages 83
 - materials for 78
 - procedure for 80
- Cloning of oligonucleotides, into lentiviral vector 110
 - materials for 110
 - methods for 111–112
- Cy5.5-NHS ester dye, MN conjugation to 6

D

- Dephosphorylate 112
- Dithiothreitol (DTT) 130
- Drosophila melanogaster* 109
- dsRNA
 - direct injection of 68
 - injection into adult mosquitoes 66, 70–71
 - synthesis of
 - piggyBac* expression vectors 68
 - steps in 64, 65, 69–70
- DTT, *see* Dithiothreitol (DTT)
- Dual-purpose nanoparticle platform for siRNA delivery, *see* MN-NIRF-siRNA

E

- EGFP amplification, primers used for 17
- egfp22 siRNA 17
- Electrophoresis sample buffer 130
- Electropulsation 16
- Embryo generation/manipulation/injection
 - materials for 111
 - methods for 113–114
- EphA2
 - downregulation in ovarian tumors 34–37
 - expression in tumor cells 31
 - staining for 32
- EphA2 siRNA-DOPC, downregulation in ovarian tumors 35–36
- Ethidium bromide 25
- Exon junction primers 130
- Ex vivo* fluorescence optical imaging, of mice bearing
 - bilateral 9L-GFP and 9L-RFP tumors 11

F

- fALS, *see* familial amyotrophic lateral sclerosis (fALS)
- familial amyotrophic lateral sclerosis (fALS)
 - RNAi-based therapy for 88
- FBS, *see* Fetal bovine serum (FBS)
- Fetal bovine serum (FBS) 31
- First-strand cDNA synthesis (RT-PCR), of
 - theophylline-responsive riboswitch 140

G

- G93A SOD1 mice, viral-mediated RNAi against
 - SOD1 in
 - AAV6 99–100
 - neuroprotection analysis following
 - motor neuron counts 104
 - myelinated fiber counts 104–105
 - transduction and SOD1 silencing analysis
 - following 102–104
 - VSV-G-pseudotyped lentivirus 97–99
- Gene silencing, of CEA by RNAi 134
- Genotyping, of transgenic animals
 - materials for 111
 - methods for 114
- GFP gene expression in tumors
 - fluorescence analysis 20–21, 25
 - statistical analysis 21–22
- GFP marker gene 115
- Glycogen 131

H

- Hairpin RNAi
 - establishment of transgenic lines expressing 71
 - vectors 54
- hCG, *see* human Chorionic Gonadotropin (hCG)
- HEK 293 cells 116
 - preparation 112
- HeLa cells, transient transfection of 140
- HeLa nuclear extract, for *in vitro* splicing 131
- HeyA8 cells
 - EphA2 downregulation in 34–37
 - fluorescent siRNA in 34
 - in vivo* siRNA distribution in 39
- Histone methylation using ChIP 120–121, 122–123
- HIV-1 LTR 120
- human Chorionic Gonadotropin (hCG) 111

I

- ImageJ software 131
- Intramuscular injections 91
- Intraperitoneal injection 84
- Intraspinal injections 90–91
- In vitro* splicing assay, of theophylline-responsive
 - riboswitch 138
- In vitro* transcription, of theophylline-responsive
 - riboswitch 138
- In vivo* fluorescence optical imaging
 - of mice bearing bilateral 9L-GFP and 9L-RFP
 - tumors 8, 10
 - parameters used for 9

K

- Kodak Scientific Imaging System 11–12

L

- Lentiviral embryo injection 115
- Lentiviral packaging plasmids 111
- Lentiviral RNAi in mice
 - advantages of 114–115
 - disadvantages of 115
- Lentiviral transgenesis 114–115
 - RNAi *in vivo* by 115
- Lentiviral vector, cloning of oligonucleotides into
 - materials for 110
 - methods for 111–112
- Lentivirus
 - and adeno-associated virus serotype 6,
 - comparison of 93
 - based on EIAV 88–89
 - generation of
 - material 110–111
 - methods for 112–113
 - pseudotyped with vesicular stomatitis virus G 89
 - recombinant
 - cell culture and transfection of 94–95
 - isolation and concentration 95
- Lentivirus RNAi vectors 53–54
- Lipofectamine 2000 Transfection Reagent 141
- Liposomal siRNA
 - DOPC 30–31
 - preparation for *in vivo* delivery 33
- Lysis buffer 130

M

- Malaria, mosquito vector and 63
- MCF7 cells, transient transfection of 135
- 7mG(ppp)G RNA cap structure analog 131
- microRNA (miRNA) 30
- 25 mM Theophylline 131
- MN
 - conjugation to Cy5.5-NHS ester dye 6
 - synthesis of, dextran-coated 4
- MN-(Cy5.5)(MPAP), conjugation of siRNA to 6–7
- MN-NIRF-siRNA
 - delivery to tumors, imaging of
 - materials for 3
 - MRI 7–8
 - near-infrared optical imaging 8
 - synthesis
 - conjugation 6–7
 - dextran-coated MN 5
 - materials for 2–3, 11
 - steps 4
 - target gene silencing assessment
 - ex vivo* fluorescence optical imaging 11
 - in vivo* fluorescence optical imaging 8–11
- Molecular Dynamics PhosphorImager 131
- Mosquito biology 63
- Myristoylated polyarginine membrane translocation
 - module (MPAP), conjugation to MN 6

N

- NOD mouse, *see* Nonobese diabetic (NOD) mouse
- Nonobese diabetic (NOD) mouse 110
- Nuclear run-on assays 123–124

O

Oligonucleotides cloning, into lentiviral vector
 materials for 110
 methods for 111–112
 Opti-MEM® 56, 129, 135
 Ovarian tumors, EphA2 silencing in
 cell culture
 material for 31
 methods 32–33
 confocal microscopy of 40
 HeyA8 cells
 EphA2 downregulation in 34–35
 fluorescent siRNA in 34
 immunohistochemistry of
 Alexa-555 fluorescent siRNA uptake 32, 38
 EphA2 staining 32, 37–38
 macrophages 38–39
 tumor vasculature 39–40
 orthotopic *in vivo* model of advanced 33–34
 transfection with siRNA
 cell preparation for 33
 materials for 31

P

piggyBac expression vectors 68
 32P-labeled ABT4M pre-mRNA 137
 Plaque assays 57
 PMS gonadotropin, *see* PregnantMare Serum (PMS)
 gonadotropin
 Polyacrylamide gel 130
 Polyvinylidene fluoride (PVDF) membrane 134
 PregnantMare Serum (PMS) gonadotropin 111
 pre-mRNA splicing 127–128
cis-acting elements of 127
 materials for 129–132
 RNAi 129
 theophylline-responsive riboswitch 130–132
 Western Blotting detection reagents 129–130
 methods for 132–140
 siRNA-mediated degradation of CEA
 mRNA 132–136
 theophylline-responsive riboswitch 136–140
 theophylline-responsive riboswitch for
 modulation of 137
 Prophylactic treatment 57
 P76 siRNA 17
 Pulmonary gene silencing by nasal administration .. 79, 84

R

Radioimmunoprecipitation assay (RIPA) lysis buffer ... 31
 Recombinant lentivirus
 cell culture and transfection of 94–95
 isolation and concentration 95
Renilla luciferase gene 116
 Riboswitches 128–129
 RISC, *see* RNA-induced silencing complex (RISC)
 RNA duplexes 55
 RNAi, *see* RNA interference (RNAi)
 RNAi expression plasmid, design and cloning of 71
 RNAi-mediated silencing in, *Anopheles* mosquitoes
 efficiency of 65
 analysis of 66–67
 at protein level 72–73

at transcriptional level 72
 injection of dsRNA 64, 66
 stable 64–65
 RNA-induced silencing complex (RISC) 128
 RNA interference (RNAi) 1, 109–110
 against CEA 133–134
 downregulation of gene expression by 115
 as gene-silencer strategy 128
 innate immunity against viruses 29
 materials for 110–111, 129
 obstacles in applying 2
 potential for tumor therapy 2
 siRNAs and 43–44
in vivo by lentiviral transgenesis 125
 RNasin 131
 Running buffer 31

S

SDS-PAGE electrophoresis reagents 45–46
 Sequa-gel sequencing system kit 131
 Short hairpin RNA (shRNA) 44, 88, 92, 110
 Short interfering RNA (siRNA) 109–110
 activity in cells 46–48
 annealing of 45
 cell lines for screening 45
 design of 52, 132–133
 guidelines for 133
 DOPC for *in vivo* delivery of 30–31
 efficacy against viruses, assays to evaluate
 cell cytotoxicity 51
 RT-PCR and Q-PCR 49
 virus plaque assay 48
 western blot analysis 49–51
 efficacy measurement by PCR 58
 incorporated into RISC 29–30
 knockdown of virus replication 56, 57
 limitation to clinical use of 59–60
 lipid-based transfection of 53
 liposomal formulations incorporated into, *see*
 Liposomal siRNA
 mediated degradation of CEA mRNA, methods for
 132–136
 and microRNAs 119
 off-targeting of 54
 promoter-targeting 120, 121–122
 selection of optimal 25
 synthetic 44
 for therapy, limitations encountered in 15–16
 time-dependence of knockdown induced by 21, 22
 transfection of cancer cells with 31
 transfection of cells with 56
 treatment of cells with 15
 uptake and distribution in ovarian tumors 34
 siRNA, *see* Short interfering RNA (siRNA)
 siRNA delivery method 44
 cell cytotoxicity and 59
 development and optimization of 2
 lipid-mediated transfection 45
 MN-NIRF-siRNA, *see* MN-NIRF-siRNA
 obstacle to 77
 viral-mediated transduction 45
 siRNA duplexes
 design 52
 for targeting mRNA 44–45
 target sites 51–52

siRNA-mediated endogenous gene silencing, electrical treatment for	
in B16-F10 GFP tumors, <i>see</i> B16-F10 GFP tumors	
GFP fluorescence expression	19
quantitative evaluation of	20–21
statistical analysis	21–22
materials for	
C57Bl/6 mice	17
cell culture	16
DNA oligonucleotides	17
mRNA extraction and analysis	18
siRNAs	16–17
<i>in vivo</i> visualization of	18
siRNA-mediated gene silencing	30
Splicing loading buffer	131
Splicing stop buffer	131
Superovulate donor females	113
Superoxide dismutase 1 (SOD1)	
mutations in gene encoding for	87–88
viral-mediated RNAi against	
AAV6 delivery	99–100
analysis of transduction and SOD1 silencing following	102–104
lentivirus based on EIAV	88–89
neuroprotection analysis following	104–105
VSV-G-pseudotyped lentivirus	89
VSV-G-pseudotyped lentivirus delivery	97–99
Systemic macrophages, transfection and gene silencing in	84
T	
Target mRNA levels, qPCR Analysis of	24
T1D, <i>see</i> Type 1 diabetes (T1D)	
TGS, <i>see</i> Transcriptional gene silencing (TGS)	
Theophylline-mediated modulation, of alternative splicing	
<i>in vivo</i>	139–140
Theophylline-responsive riboswitch	
design of	136–137
materials for	130–132
methods for	136–140
control of alternative splicing <i>in vivo</i>	139–140
first-strand cDNA synthesis (RT-PCR)	140
for modulation of pre-mRNA splicing	
<i>in vitro</i>	137
transient transfection of HeLa cells	140
<i>in vitro</i> splicing assay	138
<i>in vitro</i> transcription	138
Time-course optical imaging	
<i>ex vivo</i> fluorescence optical imaging, <i>see Ex vivo</i> fluorescence optical imaging	
silencing effect identification using	12
<i>in vivo</i> fluorescence optical imaging, <i>see In vivo</i> fluorescence optical imaging	
Transcriptional gene silencing (TGS)	119
histone methylation assessment	
chromatin marks	122–123
materials for	120–121
measurement using nuclear run-on	
materials for	121
methods for	123–124
potential therapeutic applications of	120
promoter-targeting siRNA, design of	120–122
siRNA-mediated, efficacy of	121
transfection-mediated cell cytotoxicity	51
Transfer buffer	32
Transgenic animals, genotyping of	
material for	114
materials for	111
Transgenic mosquitoes	
expressing hairpin RNAs, establishment of	66
stable RNAi gene silencing in	64–65
Transient transfection	
of HeLa cells	140
of MCF7 cells	135
Tris-buffered saline with Tween-20 (TBST)	32
T7 RNA polymerase	132
Tumor model, mouse	
MRI of	7–8
near-infrared optical imaging of	8
target gene silencing assessment	
<i>ex vivo</i> fluorescence optical imaging	11
<i>in vivo</i> fluorescence optical imaging	8–11
Type 1 diabetes (T1D)	110
V	
VSV-G-pseudotyped lentivirus	
histology of	91–92
intraspinal delivery	
into adult Mice	97–99
into presymptomatic SOD1 Mice	89
production of	89–90
W	
Western blot analysis, for siRNA-mediated degradation of	
CEA mRNA	135–136
Western blotting	31–32, 35–37
Western Blotting detection reagents	129–130
Whole-body optical imaging system	3, 4, 8, 11
X	
α-XEA T84.66	130
5x first-strand buffer for cDNA synthesis	130
2x gel loading buffer	130
2x PK buffer	131
10x transcription master mix	131